9a38d0dc-6b2c-439d-b10e-efd0f1cba209
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.300
- G2M_CHECKPOINT+0.200
- MITOTIC_SPINDLE+0.200
- MYC_TARGETS_V1+0.200
- NOTCH_SIGNALING+0.200
- SPERMATOGENESIS+0.200
- TGF_BETA_SIGNALING+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- ANGIOGENESIS+0.100
- E2F_TARGETS+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- APOPTOSIS-0.400
- COMPLEMENT-0.400
- FATTY_ACID_METABOLISM-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- BILE_ACID_METABOLISM-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ec882950-7595-4ab7-a8b8-86d1422a948a | — | — | 0.838 |
| 2 | C3N-02435 | — | cohortSQ1 | 0.833 |
| 3 | f2c3b90a.7e75.4a2a.925e.29eb9a2acac2 | — | cohortA3 | 0.833 |
| 4 | SRR8613768 | — | E | 0.831 |
| 5 | TCGA-56-8083-01A-11R-2247-07 | — | cohortMD1 | 0.830 |
| 6 | 20130253.TNBC | — | E | 0.817 |
| 7 | SRR11296886 | — | — | 0.811 |
| 8 | TCGA-D8-A1XD-01A-11R-A14D-07 | — | B | 0.811 |
| 9 | TCGA-50-6591-01A-11R-1755-07 | — | cohortMD1 | 0.803 |
| 10 | SRR17866827 | — | — | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |